Filing Details
- Accession Number:
- 0001725160-22-000069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-04-05 18:53:12
- Reporting Period:
- 2022-04-04
- Accepted Time:
- 2022-04-05 18:53:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 823607803 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1807359 | Epperly Melissa B, | C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway, Suite 1710 New York NY 10018 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-04-04 | 8,094 | $48.75 | 256,400 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-04-04 | 1,303 | $49.90 | 255,097 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-04-04 | 2,818 | $50.70 | 252,279 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-04-04 | 4,512 | $51.99 | 247,767 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-04-04 | 353 | $52.44 | 247,414 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.35 to $49.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.38 to $50.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.38 to $51.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.41 to $52.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.41 to $52.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.